Insurance Brokers

Ryan Specialty

Ryan Specialty Reports 2026 Q1 Revenue Growth of 15.2% and Launches Empowerment Program

Ryan Specialty released FY2026 Q1 earnings on April 30 After-Market EST, actual revenue USD 782.9 M (forecast USD 778.48 M), actual EPS USD 0.13 (forecast USD 0.1509)

Ryan Specialty to release FY2026 Q1 earnings on April 30 After-Market EST, forecast revenue USD 778.48 M, EPS USD 0.1509

Ryan Specialty Holdings Director Buys More Shares

RYAN Director Purchases Shares Showing Confidence in the Company

Morgan Stanley downgrades Ryan Specialty's target price to $55.00 from $61.00

Citibank and BofA Securities Maintain Buy Rating on Ryan Specialty Group

Cantor Fitzgerald analyst maintains hold rating on Ryan Specialty Group

William Blair Analyst Maintains Buy Rating on Ryan Specialty

Ryan Specialty released FY2025 Q4 earnings on February 12 After-Market EST, forecast revenue USD 774.15 M, forecast EPS USD 0.193

Ryan Specialty released FY2025 annual earnings on February 12 After-Market EST, actual revenue USD 2.995 B (forecast USD 3.078 B), actual EPS USD 0.4652 (forecast USD 0.671)

Ryan Specialty Reports Q4 Revenue Growth of 13.2%, Misses Estimates

Ryan Specialty Announces Q4 2025 Earnings and Long-term Plan

Ryan Specialty to Release FY2025 Q4 Earnings on February 12, 2026 After-Market EST, Forecast Revenue USD 774.15 M, EPS USD 0.193

Cantor Fitzgerald lowers Ryan Specialty Holdings target price to $52

Ryan Specialty Holdings Inc Class A Target Price Median Downgraded

Allspring Increases Stake in Ryan Specialty, Analysts Cut Price Targets

Ryan Specialty Holdings CEO Sells Shares and Board Member Resigns

Squarepoint Ops LLC reduced holdings in Ryan Specialty Holdings Inc

Ryan Specialty Holdings insiders sold $6.946M shares

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

RYAN

Ryan Specialty Holdings, Inc.'s average stock price target has been reduced from $42.83 to $42.5, suggesting a potential upside of 29% based on the May 20 closing price. The consensus rating remains 'Buy' among 21 analysts, with 11 Buys, 8 Holds, and 2 Sells.

TradingView

Factset Research

Ryan Specialty Holdings, Inc. Stock 12‑Month Price Target Cut to $42.5, Implies 29% Upside

Pomerantz Law Firm is investigating claims on behalf of investors of Ryan Specialty Holdings, Inc. (NYSE: RYAN) regarding potential securities fraud or unlawful business practices by the company and its officers. Following the company's fourth quarter 2025 financial results, which showed a decline in organic revenue growth and a significant drop in stock price by 12.78%, investors are encouraged to contact Pomerantz for more information about joining the class action.

prnewswire

19:01 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ryan Specialty Holdings, Inc. - RYAN

Yesterday's closing price for Ryan Specialty was $40.72, a slight decline of 0.25% during the day, with trading volume slightly increasing. The MACD daily chart confirmed a death cross signal, indicating that the upward momentum is hindered, and a technical adjustment may strengthen, leading to an overall weakening of the insurance sector. On the macro front, the market's outlook on the profitability prospects of the insurance industry is cautious, and the increased uncertainty from Federal Reserve decisions is putting liquidity pressure on the financial markets. Although the company has good risk management capabilities, sector rotation makes it difficult for it to strengthen in the short term. The technical indicators provide limited guidance, and the stock price will test support in the $40 area, with its effectiveness yet to be verified. If it fails to stabilize and challenges $42 again, the consolidation pattern that has lasted for several months may be broken. The short-term trend remains bearish, with increasing adjustment risks. Investors should approach insurance-related products cautiously and pay attention to market trends, adopting necessary conservative investment strategies to mitigate risks. This article is for analysis reference only; investment carries risks, and decisions should be made prudently

Technical Forecast

SPDR S&P Insurance

iShares US Insurance

Pre-market trend | Ryan Specialty (RYAN) 5/1 Insurance sector weakens, can the bulls regain momentum?

Earnings Watch

Ryan Specialty | 10-Q: FY2026 Q1 Revenue: USD 795.23 M

Ryan Specialty Group Holdings, Inc. reported a strong Q1 with a 15% revenue increase to $795 million, driven by organic growth. Adjusted EBITDAC rose 15.7% to $232 million, and EPS grew 20% to $0.47. However, management revised full-year organic growth expectations to 4-6% due to market pressures, particularly in property rates, which are declining by 25-35%. The company remains committed to capital allocation strategies, including share repurchases and M&A, while leveraging AI for operational efficiency. Leadership announced a stock option grant to align interests with shareholders.

Tip Ranks

Ryan Specialty Earnings Call: Growth Meets Market Pressure

SMMT

TREE

RBLX

ATMU

SNDX

ALHC

Summit Therapeutics(SMMT) fell 24.91%, with a trading turnover 290.9 Million USD, and a year-to-date fell 7.9%. LendingTree(TREE) fell 21.74%, with a trading turnover 59.4 Million USD, and a year-to-date fell 26.9%. Insperity(NSP) fell 19.79%, with a trading turnover 60.1 Million USD, and a year-to-date fell 24.2%.

Top Gainers&Losers

Summit Therapeutics

LendingTree

Insperity

Roblox

Atmus Filtration Tech

Syndax Pharma

Dolby Laboratories

Alignment Healthcare

Top 10 US Stock Losers (5.1)

Ryan Specialty Holdings, Inc. reported Q1 2026 revenue of $795.2M, a 15.2% increase from $690.2M a year ago, with net income of $17.6M and diluted EPS of $0.13, recovering from a loss of $(27.6M) last year. The growth was driven by a 15.8% rise in net commissions and fees. The company also launched a three-year Empower Program, anticipating $160M in one-time charges and $80M in annual savings by 2029. Headcount increased by 10.6% to support growth and acquisitions.

RYAN SPECIALTY HOLDINGS, INC. 1Q 2026: Revenue $795.2M, EPS $0.13— 10-Q Summary

Ryan Specialty Holdings Inc. (NYSE:RYAN) has declared a quarterly dividend of $0.13 per share, payable on May 26th to shareholders of record as of May 12th. This results in an annualized dividend yield of 1.5%. The company reported a quarterly EPS of $0.47, exceeding estimates, with revenue of $795.23 million, up 15.2% year-over-year. Ryan Specialty has a payout ratio of 20.3% and is expected to maintain its dividend coverage. The stock is currently trading at $34.75, with a market cap of $9.18 billion.

Market Beat

SBI Holdings, Inc.

Fifth Third Bancorp

Fifth Third Bancorp Pref Share FITBO 4.95 Perp 09/30/24 K

FIFTH THIRD BANK PREF SHARE FITB V6.625 P12/31/49 I

Fifth Third Bancorp Pref Shares FITBM 6.875 Perp 10/01/30

Fifth Third Bancorp Depositary Shs B Ser A Repr 1/40 6 % Perp Pfd Registered Shs B Ser A

Ryan Specialty Holdings Inc. Declares Quarterly Dividend of $0.13 (NYSE:RYAN)

INGM

Ingram Micro Holding shares are trading lower. The company reported Q1 financial results.

benzinga_article

Ingram Micro

Ryan Specialty(RYAN.US)